Tekla Capital Management’s Bicycle Therapeutics BCYC Stock Holding History

Tekla Capital Management’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$1.13M	Sell	44,338 -44,338	-50%	-$1.03M	0.04%	129
2023 Q1	$1.89M	Hold	88,676	–	–	0.07%	122
2022 Q4	$2.62M	Hold	88,676	–	–	0.1%	104
2022 Q3	$2.06M	Buy	88,676 +68,611	+342%	+$1.63M	0.08%	111
2022 Q2	$337K	Buy	20,065 +9,979	+99%	+$210K	0.01%	161
2022 Q1	$443K	Buy	+10,086	New	+$471K	0.02%	162

Other funds holding BCYC

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Tekla Capital Management's BCYC Position: Q2 2023 in Review

Tekla Capital Management reduced its Bicycle Therapeutics (BCYC) stake by 50% in Q2 2023, selling an estimated $1.03M and leaving 44,338 shares worth $1.13M. The position accounts for 0.04% of the portfolio, ranked #129.

Tekla Capital Management first reported a position in BCYC in Q1 2022 and has held it in 6 quarters since. The position peaked at $2.62M in Q4 2022. 85 funds tracked by Wall St. Rank hold BCYC as of Q2 2023.

Tekla Capital Management held 44,338 shares of Bicycle Therapeutics worth $1.13M as of Q2 2023.
Tekla Capital Management sold 44,338 Bicycle Therapeutics shares in Q2 2023, an estimated $1.03M.
Bicycle Therapeutics made up 0.04% of Tekla Capital Management's portfolio in Q2 2023, its #129 holding.
Tekla Capital Management first reported a position in Bicycle Therapeutics in Q1 2022 and has held it in 6 quarters since.
Tekla Capital Management's Bicycle Therapeutics position peaked at $2.62M in Q4 2022.
85 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.